the tricyclic antidepressant drug desipramine ( dmi ) was evaluated in the treatment of young patients with attention deficit disorder with hyperactivity ( addh ) in an unselected sample of 62 clinically referred patients , 43 ( 69 % ) of whom previously responded poorly to psychostimulant treatment .
C0011685
desipramine
C1263846
with attention deficit disorder